Published in Women's Health Weekly, March 17th, 2005
The study is the first to show that a gel can retain antiviral activity within the human vagina.
It was funded by the U.S. National Institutes of Health (NIH) and investigated the efficacy of PRO 2000, a topical microbicide under development by Indevus Pharmaceuticals, Inc.
"There is an urgent need for the development of safe and effective vaginal microbicides," Marla Keller, MD, assistant professor of Medicine at the Mount Sinai...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly